Skip to content

Pfizer’s Covid Pill Doesn’t Work For Healthier Patients, Will Focus on Those With Higher Risk

  • Covid pill produced lackluster results in lower-risk people
  • Company plans to focus on patients with high unmet need
Pfizer’s Paxlovid antiviral medication

Pfizer’s Paxlovid antiviral medication

Photographer: Kobi Wolf/Bloomberg
Updated on

Pfizer Inc. plans to stop enrollment in a study of its Covid-19 drug in patients who aren’t at high risk of severe disease after the pill didn’t help alleviate their symptoms, a major setback for broader use of the treatment. 

The New York-based drugmaker said Tuesday that it would stop adding new participants to a highly anticipated study testing Paxlovid in a broader population of Covid patients who are at low risk of hospitalization and death. The decision comes after the study failed to demonstrate that the drug reduced Covid symptoms among relatively healthy patients and wasn’t able to show a statistically significant reduction in hospitalization and death.